Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S65487 Monotherapy in Relapsed/Refractory Hematologic Malignancies
NCT03755154Phase 1Terminated
- Sponsor
- Servier
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of VOB560 in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and 1 more (2 arms), sponsored by Servier. Primary endpoints: Incidence of Dose Limiting Toxicity, Incidence and severity of Adverse Events and 4 more. Started Jul 2019; status: terminated.
02
Drugs
VOB560
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03755154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755154.